Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Drug Resistance

Free Subscription Articles published in Clin Infect Dis Retrieve available abstracts of 99 articles: HTML format

Single Articles

October 2025
1. LEE YT, Chen SC
   Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality.
   Clin Infect Dis. 2025 Oct 10:ciaf493. doi: 10.1093.
   PubMed    
   
   
   September 2025
2. POGUE JM, Kaye KS
   Actually, it may be time to return to colistin and meropenem in some patients infected with Carbapenem-resistant A. baumannii (CRAB).
   Clin Infect Dis. 2025 Sep 26:ciaf534. doi: 10.1093.
   PubMed    
   
   
   
3. MARAOLO AE, Ceccarelli G
   It is time to go beyond the association between colistin and meropenem for invasive carbapenem-resistant Acinetobacter baumannii infections.
   Clin Infect Dis. 2025 Sep 26:ciaf533. doi: 10.1093.
   PubMed    
   
   
   
4. TAWEESUK A, Rattanaumpawan P, Rachakhom S, Wangchinda W, et al
   Cluster-randomized Controlled Trial of Enhanced Carbapenem-resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital.
   Clin Infect Dis. 2025 Sep 22:ciaf523. doi: 10.1093.
   PubMed     Abstract available
   
   
   July 2025
5. HURALSKA M, Pogue JM, Rybak M, Abdul-Mutakabbir JC, et al
   The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of Patients With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens.
   Clin Infect Dis. 2025 Jul 19:ciaf398. doi: 10.1093.
   PubMed     Abstract available
   
   
   June 2025
6. REDMOND SN, Cadnum JL, Jencson AL, Kaple CE, et al
   Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital.
   Clin Infect Dis. 2025;80:984-991.
   PubMed     Abstract available
   
   
   May 2025
7. BALBUENA JP, Cordova E, Mykietiuk A, Farina J, et al
   Carbapenem-resistant Gram-negative bacilli bacteremia in Argentina (EMBARCAR): findings from a prospective, multicenter cohort study.
   Clin Infect Dis. 2025 May 20:ciaf259. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. WINTERING A, Bonifacius A, Tischer-Zimmermann S, de Oliveira Mekonnen A, et al
   Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection.
   Clin Infect Dis. 2025 May 14:ciaf125. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. BROWN KA, Fridman DJ, Garber GE, Johnstone J, et al
   The Burden of Antimicrobial Resistant Bacteremia in Ontario: A Population-wide Analysis of Attributable Mortality from 110 Pathogen-Antibiotic Combinations.
   Clin Infect Dis. 2025 May 13:ciaf213. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. CHEVALIER JM, Hansen MA, Blumel B, Chuchu V, et al
    Modeling the impact and cost of a culture-dependent molecular test for antimicrobial resistance in resource-limited settings.
    Clin Infect Dis. 2025 May 12:ciaf236. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
11. GRENNAN T, Hull MW
    Responsible use of doxycycline for STI prevention includes both recognizing its benefits and planning for antimicrobial resistance monitoring.
    Clin Infect Dis. 2025 Apr 30:ciaf220. doi: 10.1093.
    PubMed    
    
    
    
12. HAO J, Liu X, Wang D, Hu H, et al
    Transmitted Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance Among Newly Diagnosed Individuals in 31 Provincial-Level Administrative Divisions in China in 2023: A Cross-sectional Survey.
    Clin Infect Dis. 2025 Apr 29:ciaf159. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. BIRABAHARAN M
    Vancomycin-Resistant Enterococci-Active Perioperative Prophylaxis for Liver Transplant Patients Requires Attention to the Gut Microbiota.
    Clin Infect Dis. 2025 Apr 22:ciaf168. doi: 10.1093.
    PubMed    
    
    
    March 2025
14. CUELLA-MARTIN I, Hakizayezu F, Ahmed A, Runyambo D, et al
    Paucibacillary tuberculosis drives the low positive predictive value of Xpert MTB/RIF Ultra for rifampicin resistance detection in low-prevalence settings.
    Clin Infect Dis. 2025 Mar 22:ciaf132. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. ROGG L, Underwood M, Hanan N, Castillo-Mancilla JR, et al
    Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.
    Clin Infect Dis. 2025 Mar 21:ciaf135. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. BURASTERO GJ, Wey EQ, Guidetti V, Cantergiani S, et al
    Impact of VRE-active perioperative prophylaxis in liver transplant patients colonized by Vancomycin-Resistant Enterococci.
    Clin Infect Dis. 2025 Mar 14:ciaf121. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. CHARPENTIER C, Berzow D, Le Hingrat Q, Kaiser R, et al
    HIV-2EU - Supporting Standardized HIV-2 Drug Resistance Interpretation: an Update.
    Clin Infect Dis. 2025 Mar 12:ciaf110. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. DE MIGUEL R, de Lagarde Sebastian M, Blanco Arevalo JL, Pinto-Martinez A, et al
    Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons with Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicentre, Phase IIA Clinical Trial.
    Clin Infect Dis. 2025 Mar 7:ciaf100. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
19. SOGE OO, Thibault CS, Cannon CA, McLaughlin SE, et al
    Potential Impact of Doxycycline Post-Exposure Prophylaxis on Tetracycline Resistance in Neisseria gonorrhoeae and Colonization with Tetracycline-Resistant Staphylococcus aureus and Group A Streptococcus.
    Clin Infect Dis. 2025 Feb 28:ciaf089. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. STEFANOVIC A, Alam ME, Matic N, Larnder A, et al
    Increased Severity of Multidrug-Resistant Shigella sonnei Infections in People Experiencing Homelessness.
    Clin Infect Dis. 2025;80:339-346.
    PubMed     Abstract available
    
    
    
21. HSU AJ, Chiotos K, Heil EL, Shields RK, et al
    The Effectiveness of Newer Beta-Lactams for the Treatment of Antimicrobial-Resistant Gram-Negative Meningitis.
    Clin Infect Dis. 2025 Feb 20:ciaf071. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. SHAH S, Kline EG, Haidar G, Squires KM, et al
    Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia.
    Clin Infect Dis. 2025;80:24-28.
    PubMed     Abstract available
    
    
    January 2025
23. CHEMALY RF, Shafat T, Wald A, Kotton CN, et al
    Refractory and Resistant Herpes Simplex Virus Mucocutaneous Infections in Immunocompromised Patients: Literature Review and Proposed Definitions for Use in Clinical Trials.
    Clin Infect Dis. 2025 Jan 29:ciae638. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. VENA A, Tiseo G, Falcone M, Bartalucci C, et al
    Impact of Fluconazole Resistance on the Outcomes of Patients With Candida parapsilosis Bloodstream Infections: A Retrospective Multicenter Study.
    Clin Infect Dis. 2025 Jan 15:ciae603. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2024
25. MONTROUGE T, Bertine M, Peytavin G, Saint Joannis T, et al
    Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy with Lenacapavir-Containing Regimen.
    Clin Infect Dis. 2024 Dec 31:ciae650. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. PEREZ NAVARRO A, Nutt CT, Siedner MJ, McCluskey SM, et al
    Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long acting cabotegravir for HIV treatment: A meta-analysis.
    Clin Infect Dis. 2024 Dec 26:ciae631. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. HAN WM, Solomon S, Smeaton L, Avihingsanon A, et al
    Reinfection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trial.
    Clin Infect Dis. 2024 Dec 20:ciae627. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. RAWSON JMO, Donaldson EF, O'Rear JJ, Harrington PR, et al
    Independent FDA Analyses of Nirmatrelvir/Ritonavir Resistance in the Phase 2/3 Trials EPIC-HR and EPIC-SR.
    Clin Infect Dis. 2024 Dec 17:ciae615. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. AUMA E, Alberts R, Derendinger B, Venter R, et al
    Diagnostic accuracy of LiquidArray MTB-XDR VER1.0 for the detection of Mycobacterium tuberculosis complex, fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility.
    Clin Infect Dis. 2024 Dec 12:ciae614. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2024
30. FERRAN E, Chan C, Sheikh N, Dedicoat M, et al
    Population-level frequency of fluoroquinolone resistance by whole-genome sequencing drug predictions in Mycobacterium tuberculosis complex isolates in England from 2017-2023.
    Clin Infect Dis. 2024 Nov 13:ciae560. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
31. DHAR S, Jinadatha C, Kilgore PE, Henig O, et al
    Lowering the Acquisition of Multidrug-Resistant Organisms (MDROs) With Pulsed-xenon (LAMP) Study: A Cluster-Randomized, Controlled, Double-Blinded, Interventional Crossover Trial.
    Clin Infect Dis. 2024;79:1024-1030.
    PubMed     Abstract available
    
    
    
32. HICKEY MD, Gistand N, Grochowski J, Mayorga-Munoz F, et al
    48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia.
    Clin Infect Dis. 2024 Oct 5:ciae500. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. INZAULE S, Easterbrook P, Latona A, Ford NP, et al
    Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.
    Clin Infect Dis. 2024 Oct 3:ciae431. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. VIRK HS, Biemond JJ, Earny VA, Chowdhury S, et al
    Unraveling Sepsis Epidemiology in a Low- and Middle-Income Intensive Care Setting Reveals the Alarming Burden of Tropical Infections and Antimicrobial Resistance: A Prospective Observational Study (MARS-India).
    Clin Infect Dis. 2024 Oct 1:ciae486. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
35. OGBUAGU O, Molina JM, Chetchotisakd P, Ramgopal MN, et al
    Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial.
    Clin Infect Dis. 2024 Aug 29:ciae423. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. GOODLET KJ, Nailor MD
    Central Nervous System Infections and Antibiotic Selection: All Infection Sites Are Not Created Equal.
    Clin Infect Dis. 2024;79:573-574.
    PubMed    
    
    
    
37. TAMMA PD, Heil EL, Justo JA, Mathers AJ, et al
    Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
    Clin Infect Dis. 2024 Aug 7:ciae403. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2024
38. LJUNGMAN P, Chemaly RF, Khawaya F, Alain S, et al
    Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum.
    Clin Infect Dis. 2024 Jul 23:ciae321. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. BOUTIN CA, Durocher F, Beauchemin S, Ziegler D, et al
    Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review.
    Clin Infect Dis. 2024;79:151-160.
    PubMed     Abstract available
    
    
    
40. EUBANK TA, Dureja C, Garey KW, Hurdle JG, et al
    Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response.
    Clin Infect Dis. 2024;79:15-21.
    PubMed     Abstract available
    
    
    
41. GROSSMAN MK, Rankin DA, Maloney M, Stanton RA, et al
    Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears.
    Clin Infect Dis. 2024;79:6-14.
    PubMed     Abstract available
    
    
    
42. HEIL EL
    Put the Fluoroquinolone Down and No One Gets Hurt.
    Clin Infect Dis. 2024;79:1-2.
    PubMed    
    
    
    
43. GOTO M
    A Call for a Reinvention of Antibiogram.
    Clin Infect Dis. 2024;79:282.
    PubMed    
    
    
    June 2024
44. SENCHYNA F, Murugesan K, Rotunno W, Nadimpalli SS, et al
    Sequential Treatment Failure With Aztreonam-Ceftazidime-Avibactam Followed by Cefiderocol Due to Preexisting and Acquired Mechanisms in a New Delhi Metallo-beta-lactamase-Producing Escherichia coli Causing Fatal Bloodstream Infection.
    Clin Infect Dis. 2024;78:1425-1428.
    PubMed     Abstract available
    
    
    
45. COOPER LN, Beauchamp AM, Ingle TA, Diaz MI, et al
    Socioeconomic Disparities and the Prevalence of Antimicrobial Resistance.
    Clin Infect Dis. 2024 Jun 7:ciae313. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. SKRIVANKOVA VW, Huwa J, Muula G, Chiwaya GD, et al
    Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia.
    Clin Infect Dis. 2024 Jun 7:ciae261. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
47. PINEDA-REYES R, Neil BH, Orndorff J, Williams-Bouyer N, et al
    Clinical presentation, antimicrobial resistance, and treatment outcomes of Aeromonas human infections: A 14-year retrospective study and comparative genomics of two isolates from fatal cases.
    Clin Infect Dis. 2024 May 17:ciae272. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. GETANDA P, Jagne I, Bognini JD, Camara B, et al
    Impact of Intrapartum Azithromycin on the Carriage and Antibiotic Resistance of Escherichia coli and Klebsiella pneumoniae in Mothers and their Newborns: a sub-study of a Randomized Double-Blind Trial Conducted in The Gambia and Burkina Faso.
    Clin Infect Dis. 2024 May 16:ciae280. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. WOLFE KH, Pierce VM, Humphries RM
    How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice.
    Clin Infect Dis. 2024;78:1140-1147.
    PubMed     Abstract available
    
    
    
50. FALCONE M, Giordano C, Leonildi A, Galfo V, et al
    Clinical Features and Outcomes of Infections Caused by Metallo-beta-Lactamase-Producing Enterobacterales: A 3-Year Prospective Study From an Endemic Area.
    Clin Infect Dis. 2024;78:1111-1119.
    PubMed     Abstract available
    
    
    
51. KONU YR, Takassi E, Peytavin G, Dapam N, et al
    Pharmaco-virological outcomes and genotypic resistance profiles among children and adolescents receiving a DTG-based regimen in Togo.
    Clin Infect Dis. 2024 May 15:ciae278. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. PETERSON B, Arzika AM, Amza A, Maliki R, et al
    Assessment of spillover of antimicrobial resistance to untreated children 7 to 12 years old after mass drug administration of azithromycin for child survival in Niger: a secondary analysis of the MORDOR cluster-randomized trial.
    Clin Infect Dis. 2024 May 13:ciae267. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2024
53. TAMMA PD, Immel S, Karaba SM, Soto CL, et al
    Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis with Sulbactam-Durlobactam.
    Clin Infect Dis. 2024 Apr 17:ciae210. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. MARINER-LLICER C, Saavedra Cervera B, Mambuque E, Gomes N, et al
    Monitoring of First-line Drug Resistance Mutations Outside the Scope of Xpert MTB/RIF Ultra is Needed for Successful Control of DR-TB in Southern Mozambique.
    Clin Infect Dis. 2024;78:842-845.
    PubMed     Abstract available
    
    
    
55. SHIELDS RK, Cheng WY, Kponee-Shovein K, Indacochea D, et al
    Development of Predictive Models to Inform a Novel Risk Categorization Framework for Antibiotic Resistance in E. coli-Causing Uncomplicated Urinary Tract Infection.
    Clin Infect Dis. 2024 Apr 4:ciae171. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. TSCHUMI N, Lukau B, Tlali K, Motaboli L, et al
    Emergence of acquired dolutegravir resistance in treatment-experienced people with HIV in Lesotho.
    Clin Infect Dis. 2024 Apr 3:ciae185. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
57. 
    Correction to: Capturing Data on Antimicrobial Resistance Patterns and Trends in Use in Regions of Asia (CAPTURA) Supplement.
    Clin Infect Dis. 2024 Mar 29:ciae122. doi: 10.1093.
    PubMed    
    
    
    
58. HAZRA A, Celum C, Luetkemeyer AF, Molina JM, et al
    Risk of antimicrobial resistance with doxy-PEP is real, as is the need for its well-Informed implementation.
    Clin Infect Dis. 2024 Mar 19:ciae152. doi: 10.1093.
    PubMed    
    
    
    
59. MOHANTY S, Ye G, Sheets C, Cossrow N, et al
    Association Between Social Vulnerability and Streptococcus pneumoniae Antimicrobial Resistance in US Adults.
    Clin Infect Dis. 2024 Mar 14:ciae138. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. LANDOVITZ RJ, Tao L, Yang J, de Boer M, et al
    HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
    Clin Infect Dis. 2024 Mar 14:ciae143. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2024
61. BONOMO RA, Perez F, Hujer AM, Hujer KM, et al
    The Real Crisis in Antimicrobial Resistance: Failure to Anticipate and Respond.
    Clin Infect Dis. 2024 Jan 30:ciad758. doi: 10.1093.
    PubMed    
    
    
    
62. VAN WELZEN BJ, Van Lelyveld SFL, Ter Beest G, Gisolf JH, et al
    Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis.
    Clin Infect Dis. 2024 Jan 11:ciae016. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. URSENBACH A, Ruch Y, Hoellinger B, Fuchs A, et al
    Two cases of viral re-suppression after M184V + R263 K selection on DTG/3TC without treatment modification.
    Clin Infect Dis. 2024 Jan 9:ciae006. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2023
64. VAN DER VAART TW, Prins JM, Goorhuis A, Lemkes BA, et al
    The utility of risk factors to define complicated Staphylococcus aureus bacteremia in a setting with low MRSA prevalence.
    Clin Infect Dis. 2023 Dec 29:ciad784. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. POPOVICH KJ, Aureden K, Ham DC, Harris AD, et al
    Reply to Diekema et al. "Are contact precautions "essential" for the prevention of healthcare-associated methicillin-resistant Staphylococcus aureus?".
    Clin Infect Dis. 2023 Dec 20:ciad777. doi: 10.1093.
    PubMed    
    
    
    
66. SUJAN MJ, Habib ZH, Rahman A, Rizvi SMS, et al
    Antimicrobial Resistance Surveillance Methods in Bangladesh: Present and Way Forward.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
67. ABOUSHADY AT, Sujan MJ, Pham K, Clark A, et al
    Key Recommendations for Antimicrobial Resistance Surveillance: Takeaways From the CAPTURA Project.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
68. HOLM M, MacWright WR, Poudyal N, Shaw AG, et al
    Capturing Data on Antimicrobial Resistance Patterns and Trends in Use in Regions of Asia (CAPTURA).
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
69. MAHARJAN S, Gallagher P, Gautam M, Joh HS, et al
    Recording and Reporting of Antimicrobial Resistance (AMR) Priority Variables and Its Implication on Expanding Surveillance Sites in Nepal: A CAPTURA Experience.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
70. TADESSE BT, Keddy KH, Rickett NY, Zhusupbekova A, et al
    Vaccination to Reduce Antimicrobial Resistance Burden-Data Gaps and Future Research.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
71. GALLAGHER P, Shaw A, Bhandari A, Poudyal N, et al
    Considerations for Expanding Antimicrobial Resistance Surveillance Networks.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
72. LESLIE T, Parry C, Ondoa P, Walsh T, et al
    The Reality of Antimicrobial Resistance and Antibiotic Usage Data in Asia: The CAPTURA Experience.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
73. JOH HS, Yeats C, Shaw A, Poudyal N, et al
    Methodological Approach to Identify and Expand the Volume of Antimicrobial Resistance (AMR) Data in the Human Health Sector in Low- and Middle-Income Countries in Asia: Implications for Local and Regional AMR Surveillance Systems Strengthening.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
74. JOH HS, Dolabella B, Early E, Stelling J, et al
    CAPTURA Regional Workshop Proceedings (28-30 June 2022, Virtual).
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
75. POUDYAL N, Holm M, Joh HS, Gautam S, et al
    Effective Stakeholder Engagement for Collation, Analysis and Expansion of Antimicrobial Resistance (AMR) Data: A CAPTURA Experience.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
76. DOUD MB, Haste NM, Abeles SR
    Correspondence to Hasegawa et al. "Diagnostic Accuracy of Hospital Antibiograms in Predicting the Risk of Antimicrobial Resistance in Enterobacteriaceae Isolates: A Nationwide Multicenter Evaluation at the Veterans Health Administration".
    Clin Infect Dis. 2023 Dec 6:ciad748. doi: 10.1093.
    PubMed    
    
    
    
77. SANSOM SE, Gussin GM, Schoeny M, Singh RD, et al
    Rapid Environmental Contamination with Candida auris and Multidrug-Resistant Bacterial Pathogens Near Colonized Patients.
    Clin Infect Dis. 2023 Dec 6:ciad752. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. NHU NTQ, Young VB
    The Relationship Between the Microbiome and Antimicrobial Resistance.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    November 2023
79. MACDOUGALL C
    A Cloudy Crystal Ball: Critically Assessing and Rethinking the Antibiogram.
    Clin Infect Dis. 2023;77:1501-1503.
    PubMed    
    
    
    
80. MANHART LE, Leipertz G, Soge OO, Jordan SJ, et al
    Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data From Sexual Health Clinics in 4 US Regions.
    Clin Infect Dis. 2023;77:1449-1459.
    PubMed     Abstract available
    
    
    
81. MISRA K, Huang JS, Udeagu CN, Forgione L, et al
    Pre-exposure prophylaxis (PrEP) use history in people with antiretroviral resistance at HIV diagnosis: Findings from New York City HIV surveillance and partner services, 2015-2022.
    Clin Infect Dis. 2023 Nov 17:ciad699. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. YASSIN A, Huralska M, Pogue JM, Dixit D, et al
    Executive Summary: State-of-the-Art Review: State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms.
    Clin Infect Dis. 2023;77:1223-1225.
    PubMed    
    
    
    
83. YASSIN A, Huralska M, Pogue JM, Dixit D, et al
    State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms.
    Clin Infect Dis. 2023;77:e46-e56.
    PubMed     Abstract available
    
    
    
84. ASLAM S
    Phage Therapy in Lung Transplantation: Current Status and Future Possibilities.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    October 2023
85. EVANS SR, Patel R, Hamasaki T, Howard-Anderson J, et al
    The Future Ain't What It Used to Be...Out With the Old...In With the Better: Antibacterial Resistance Leadership Group Innovations.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
86. CHAMBERS HF, Cross HR, Souli M, Evans SR, et al
    The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
87. CROSS HR, Greenwood-Quaintance KE, Souli M, Komarow L, et al
    Under the Hood: The Scientific Leadership, Clinical Operations, Statistical and Data Management, and Laboratory Centers of the Antibacterial Resistance Leadership Group.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
88. HANSON KE, Banerjee R, Doernberg SB, Evans SR, et al
    Priorities and Progress in Diagnostic Research by the Antibacterial Resistance Leadership Group.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
89. SATLIN MJ, van Duin D, Tamma PD, Lodise TP, et al
    Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
90. JEZEK A, Del Rio C
    Antibacterial Resistance, Research, and Funding in 2024.
    Clin Infect Dis. 2023;77.
    PubMed    
    
    
    
91. HARRIS AD, Souli M, Pettigrew MM
    The Next Generation: Mentoring and Diversity in the Antibacterial Resistance Leadership Group.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
92. DOERNBERG SB, Arias CA, Altman DR, Babiker A, et al
    Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
93. STRAUB TJ, Lombardo MJ, Bryant JA, Diao L, et al
    Impact of a purified microbiome therapeutic on abundance of antimicrobial resistance genes in patients with recurrent Clostridioides difficile infection.
    Clin Infect Dis. 2023 Oct 12:ciad636. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2023
94. DIEKEMA DJ, Nori P, Stevens MP, Smith MW, et al
    Are contact precautions "essential" for the prevention of healthcare-associated methicillin-resistant Staphylococcus aureus?
    Clin Infect Dis. 2023 Sep 21:ciad571. doi: 10.1093.
    PubMed     Abstract available
    
    
    
95. WANG M, Ge L, Chen L, Komarow L, et al
    Clinical Outcomes and Bacterial Characteristics of Carbapenem-Resistant Acinetobacter baumannii Among Patients from Different Global Regions.
    Clin Infect Dis. 2023 Sep 20:ciad556. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. KASAIE P, Pennington J, Gupta A, Dowdy DW, et al
    The impact of preventive treatment for multidrug- and rifampin-resistant tuberculosis exceeds trial-based estimates.
    Clin Infect Dis. 2023 Sep 19:ciad557. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. COTTO O, Armand-Lefevre L, Matheron S, Ruppe E, et al
    Within-Host Dynamics and Duration of Colonization of Travel-Acquired Multidrug-Resistant Enterobacterales in Untreated Individuals.
    Clin Infect Dis. 2023;77:934-936.
    PubMed    
    
    
    
98. BOAST A, How JA, Lau C, Sett A, et al
    Pre-XDR congenital tuberculosis in an extremely premature baby.
    Clin Infect Dis. 2023 Sep 8:ciad540. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2023
99. HASEGAWA S, Livorsi DJ, Perencevich EN, Church JN, et al
    Diagnostic Accuracy of Hospital Antibiograms in Predicting the Risk of Antimicrobial Resistance in Enterobacteriaceae Isolates: A Nationwide Multicenter Evaluation at the Veterans Health Administration.
    Clin Infect Dis. 2023 Aug 10:ciad467. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Drug Resistance is free of charge.